Jaundice (newborn) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Newborn Jaundice – Complete Medical Guide

Newborn Jaundice – A Comprehensive Medical Guide

Overview

Jaundice in newborns is a common condition in which the baby’s skin and the whites of the eyes turn yellow. This discoloration occurs because of an excess of bilirubin, a yellow pigment produced when red blood cells break down. In most cases, newborn jaundice is harmless and resolves with simple treatment, but high bilirubin levels can become dangerous if not addressed promptly.

Who it affects: All newborns produce bilirubin, but visible jaundice typically appears in infants 2–3 days old. Preterm infants (<37 weeks gestation) are more likely to develop jaundice and to experience higher bilirubin levels.

Prevalence: According to the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), up to 60 % of full‑term and 80 % of preterm infants develop some degree of jaundice in the first week of life.[1][2] While most cases are physiologic (normal), about 5–10 % are pathologic and require closer evaluation.

Symptoms

Jaundice may be subtle at first. Below is a comprehensive list of signs parents and caregivers should watch for, along with brief descriptions.

  • Yellow discoloration of the skin: Begins on the face and progresses down the chest, abdomen, and limbs. In severe cases, the entire body turns yellow.
  • Yellowing of the sclera (white of the eyes): Often the earliest visible sign.
  • Feeding difficulties: Lethargy or poor suck reflex can be a sign that bilirubin is affecting the brain.
  • Excessive sleepiness or irritability: Babies may be unusually sleepy, difficult to arouse, or conversely, very fussy.
  • Dark urine: Bilirubin that is excreted via the kidneys can turn urine a amber or tea‑colored hue.
  • Palpable liver or spleen enlargement: May indicate hemolytic disease or infection.
    • *High‑pitch cry or “high‑frequency” crying: Rare but can indicate acute bilirubin encephalopathy.
  • Seizures or abnormal movements: Very late sign of severe hyperbilirubinemia affecting the brain (kernicterus).

Causes and Risk Factors

Primary Causes

  1. Physiologic jaundice: The most common type, caused by the newborn’s immature liver which cannot process bilirubin quickly enough. It usually peaks between days 3–5 in term infants.
  2. Breast‑feeding jaundice: Occurs in the first week when a baby does not receive enough milk, reducing bowel movements that help eliminate bilirubin.
  3. Breast‑milk jaundice: Usually appears after the first week and can persist for several weeks; thought to be linked to substances in breast milk that increase bilirubin reabsorption.
  4. Hemolytic disease of the newborn (HDN): Incompatibility between mother and baby blood types (e.g., Rh or ABO) leads to rapid red‑cell breakdown.
  5. Genetic enzyme deficiencies: Such as G6PD deficiency, Crigler‑Najjar syndrome, or Gilbert’s syndrome.
  6. Infections: Sepsis, urinary tract infection, or TORCH infections can impair bilirubin metabolism.
  7. Blood group incompatibility, liver disorders, or metabolic diseases.

Risk Factors

  • Prematurity or low birth weight (<2500 g)
  • Early clamping of the umbilical cord, which reduces blood volume
  • Bruising or large birth‑mark (cephalohematoma) that increases red‑cell breakdown
  • Exclusive breastfeeding without adequate milk intake (first 3–5 days)
  • Maternal diabetes, hypertension, or preeclampsia
  • Family history of blood‑type incompatibility or enzyme deficiencies
  • East Asian, Mediterranean, or African ancestry (higher rates of G6PD deficiency)
  • Use of certain medications (e.g., sulfonamides) by the mother during pregnancy

Diagnosis

Early recognition and accurate measurement of bilirubin are essential. The diagnostic process generally follows these steps:

1. Physical Examination

  • Assessment of skin color using the Kramer's rule (a visual scale from head to toe)
  • Examination of the sclera, fontanelles, and overall alertness

2. Bilirubin Quantification

  1. Serum total bilirubin (TSB) test: Blood sample drawn via heel stick or venipuncture. Values are plotted on the Bhutani nomogram to determine risk zones (low, intermediate, high).[3]
  2. Transcutaneous bilirubin (TcB) meter: A non‑invasive device that measures skin bilirubin; useful for screening and follow‑up but must be confirmed with a serum test if high.

3. Additional Labs (if indicated)

  • Complete blood count (CBC) – to assess hemolysis.
  • Blood type and Coombs test – to detect maternal‑infant blood incompatibility.
  • G6PD activity assay – if hemolysis is suspected in at‑risk ethnic groups.
  • C‑reactive protein (CRP) or blood cultures – if infection is a concern.

4. Imaging (rare)

Abdominal ultrasound may be ordered if there is suspicion of bile duct obstruction or liver pathology.

Treatment Options

Treatment aims to lower bilirubin safely and prevent neurotoxicity. The choice depends on bilirubin level, infant age in hours, gestational age, and presence of risk factors.

1. Phototherapy

  • How it works: Blue‑green light (≈460 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without liver conjugation.
  • Types:
    • Conventional (single or double) overhead lamps.
    • Fiber‑optic blankets or pads (useful for premature infants).
  • Duration: Usually 12–24 hours until bilirubin falls below treatment thresholds; infants are monitored every 4–6 hours.
  • Side effects: Mild dehydration, temperature instability, skin rash, or temporary silver‑gray discoloration (rare).

2. Exchange Transfusion

Reserved for bilirubin levels that threaten the brain (typically > 20 mg/dL in term infants) or when phototherapy fails. Blood is removed and replaced with donor blood in a controlled series of exchanges.

3. Intravenous Immunoglobulin (IVIG)

Used primarily for hemolytic disease due to ABO or Rh incompatibility. IVIG lowers bilirubin by reducing antibody‑mediated red‑cell destruction. Dose: 1 g/kg over 2 hours, may be repeated.

4. Enhancing Feeding

  • Frequent breastfeeding (at least 8–12 times/24 h) or supplemental formula feeds to increase stool output and bilirubin excretion.
  • If breast‑milk jaundice persists after the first week, temporary supplementation with formula is often recommended while continuing breastfeeding.

5. Medications

Specific drugs are not used to treat jaundice itself, but underlying causes (e.g., antibiotics for infection) are addressed. Phenobarbital was historically used to increase liver enzymes but is rarely employed due to side‑effects.

Living with Jaundice (newborn)

While under treatment, families can support their baby’s recovery with simple, everyday actions.

  • Feeding schedule: Offer breast milk or formula every 2–3 hours; monitor weight daily.
  • Hydration: Ensure the infant stays well‑hydrated; add a few extra ounces of expressed breast milk if the baby is feeding poorly.
  • Skin care: Keep the baby’s skin clean and dry; avoid ointments that could block light during phototherapy.
  • Temperature monitoring: During phototherapy, keep the room at 24‑26 °C (75‑79 °F) and use a thermometer to avoid overheating or hypothermia.
  • Eye protection: If phototherapy lights are overhead, special eye patches are placed to protect the retina.
  • Follow‑up appointments: Return for bilirubin checks as directed—usually within 12–24 hours after discharge.
  • Record keeping: Keep a log of feeding times, output (wet diapers, stools), and any changes in skin color.
  • Support: Reach out to lactation consultants or support groups for breastfeeding assistance.

Prevention

While not all cases are preventable, several strategies can reduce the risk or severity of newborn jaundice.

  1. Early and frequent feeding: Initiate breastfeeding within the first hour after birth and continue every 2–3 hours.
  2. Monitoring after discharge: Schedule a bilirubin check before leaving the hospital, especially for preterm infants or those with risk factors.
  3. Maternal health optimization: Control diabetes, hypertension, and treat infections during pregnancy.
  4. Blood‑type screening: Prenatal ABO/Rh testing allows for early intervention (e.g., Rh immunoglobulin).
  5. Avoid unnecessary early clamping of the cord: Delayed cord clamping (30–60 seconds) improves neonatal blood volume and reduces early jaundice.
  6. Educate caregivers: Provide written discharge instructions on what to look for and when to seek care.

Complications

If left untreated or if bilirubin rises rapidly, the following serious complications can occur:

  • Kernicterus (bilirubin‑induced neurologic dysfunction): Permanent brain damage affecting the basal ganglia, cerebellum, and hippocampus. Symptoms include abnormal eye movements, hearing loss, athetoid movements, and intellectual disability.
  • Acute bilirubin encephalopathy: Reversible early stage of kernicterus characterized by lethargy, poor feeding, and high‑pitched cry.
  • Hemolytic anemia: Ongoing red‑cell destruction can lead to low hemoglobin and require transfusion.
  • Chronic liver disease: Rare, but prolonged hyperbilirubinemia may indicate underlying metabolic or obstructive disease.

Timely phototherapy reduces the risk of kernicterus by > 95 % in term infants accordingp to the American Academy of Pediatrics (AAP).[4]

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if your baby shows any of the following signs:
  • Skin or eyes become increasingly yellow, especially spreading to the chest, abdomen, or limbs.
  • Baby is unusually sleepy, difficult to wake, or has a high‑pitched, continuous cry.
  • Feeding difficulty worsens – baby refuses feeds or vomits.
  • Seizures, stiffening, or abnormal jerking movements.
  • Fever ≥ 38 °C (100.4 °F) or signs of infection (e.g., poor perfusion, rapid breathing).
  • Dark urine or pale stools persisting beyond the first few days.

Rapid intervention can prevent irreversible brain injury.

References

  1. Mayo Clinic. “Neonatal Jaundice.” Updated 2023. https://www.mayoclinic.org
  2. Centers for Disease Control and Prevention. “Jaundice in Newborns.” 2022. https://www.cdc.gov
  3. American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” 2022 Policy Statement. https://pediatrics.aappublications.org
  4. World Health Organization. “Neonatal Jaundice: Guidelines for Diagnosis and Management.” 2021. https://www.who.int
  5. Cleveland Clinic. “Newborn Jaundice.” 2023. https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References